Journal of Cardiovascular Pharmacology最新文献_第8页

Individualized Cardiovascular Therapeutics Using Artificial Intelligence-Powered Cardiovascular Imaging. 通过人工智能驱动的心血管成像进行个体化心血管治疗。

IF 2.5 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2026-06-01 DOI: 10.1097/FJC.0000000000001788

Oluwaremilekun Zeth Tolu-Akinnawo, Andrew Greek, Dania Jaamour, Hameedah Adedoyin Azeez, Jonas Paul Ibekwe, Adeleke Oluwaseun Dorcas, Abisola C Bolarinwa, Oluwakemi A Adenuga, Jae Heon Jung, Awoyemi Toluwalase

{"title":"Individualized Cardiovascular Therapeutics Using Artificial Intelligence-Powered Cardiovascular Imaging.","authors":"Oluwaremilekun Zeth Tolu-Akinnawo, Andrew Greek, Dania Jaamour, Hameedah Adedoyin Azeez, Jonas Paul Ibekwe, Adeleke Oluwaseun Dorcas, Abisola C Bolarinwa, Oluwakemi A Adenuga, Jae Heon Jung, Awoyemi Toluwalase","doi":"10.1097/FJC.0000000000001788","DOIUrl":"10.1097/FJC.0000000000001788","url":null,"abstract":"Abstract: Cardiovascular disease remains a leading cause of global illness and death, accounting for approximately 17.9 million deaths annually, according to the World Health Organization. There is a growing need for more precise and individualized therapeutic strategies to reduce this burden. Artificial intelligence (AI) has the potential to enhance cardiovascular outcomes by facilitating personalized risk stratification and informing treatment decisions, particularly through advancements in AI-powered cardiovascular imaging and machine learning models. Traditional approaches rely on population-level risk assessments and generalized treatment guidelines, which often fail to capture the complex and diverse nature of individual patient presentations. This review examines the transformative impact of AI-enhanced cardiovascular imaging modalities, including echocardiography, cardiac magnetic resonance imaging, computed tomography angiography, and nuclear cardiology, on optimizing medical therapy. Machine learning algorithms can rapidly and accurately analyze large volumes of imaging data, improving efficiency, standardizing image acquisition and interpretation, reducing interobserver variability, and increasing diagnostic confidence. By integrating AI with cardiovascular imaging, clinicians can achieve personalized risk assessments, early disease detection, and tailored treatment plans that range from pharmacotherapy to interventions and lifestyle modifications. These advances hold promise for improving outcomes in patients with cardiovascular disease or at risk for its development. The review also addresses current challenges and future directions, highlighting the potential of AI to usher in a new era of individualized cardiovascular care.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"394-402"},"PeriodicalIF":2.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145827748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and Safety of the β 3 -Adrenergic Agonist Mirabegron in Patients With Heart Failure: An Updated Systematic Review and Meta-Analysis. β3-肾上腺素能激动剂Mirabegron在心力衰竭患者中的疗效和安全性：一项最新的系统综述和荟萃分析

IF 2.5 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2026-06-01 DOI: 10.1097/FJC.0000000000001821

Alaa Abdelhamid, Ahmed Arabi, Humam Rajha, Omar Tluli, Yaman Al-Haneedi, Dima Nasrallah, Esraa Ahmed, Ali H Eid

{"title":"Efficacy and Safety of the β 3 -Adrenergic Agonist Mirabegron in Patients With Heart Failure: An Updated Systematic Review and Meta-Analysis.","authors":"Alaa Abdelhamid, Ahmed Arabi, Humam Rajha, Omar Tluli, Yaman Al-Haneedi, Dima Nasrallah, Esraa Ahmed, Ali H Eid","doi":"10.1097/FJC.0000000000001821","DOIUrl":"10.1097/FJC.0000000000001821","url":null,"abstract":"Abstract: Heart failure (HF) remains a leading cause of global mortality. β3-adrenergic receptors are upregulated in HF, and their activation has demonstrated cardioprotective effects in preclinical studies. This systematic review and meta-analysis evaluated the efficacy and safety of the β3-adrenergic agonist mirabegron in patients with HF. Five randomized controlled trials including 538 participants were analyzed. Mirabegron showed no definitive evidence of improved physical capacity, quality of life, left ventricular ejection fraction (LVEF) (pooled mean difference of change from baseline = +0.51%, 95% CI, -4.56 to 5.57) or NT-proBNP (pooled mean difference of change from baseline = +5.42 pg/mL, 95% CI, -292.15 to 302.98). However, isolated benefits in cardiac index and pulmonary vascular resistance were noted in severe HF. Mirabegron did not demonstrate definitive evidence of safety in patients with HF, with a 4% higher odds of serious adverse events compared with placebo (odds ratio = 1.04, 95% CI, 0.63-1.72) and a 4:0 imbalance in deaths with mirabegron compared with placebo. No statistically significant changes were seen in systolic or diastolic blood pressure, heart rate, QT interval, or urinary adverse events. The GRADE certainty of evidence for LVEF, systolic blood pressure, and urinary adverse events was rated low due to serious imprecision and high risk of publication bias. Mirabegron did not demonstrate definitive evidence of improved physical capacity, quality of life, or cardiac function in HF, although isolated benefits were noted. Mirabegron's safety profile in patients with HF remains uncertain. Larger, long-term trials targeting patients with severe HF are warranted.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"486-500"},"PeriodicalIF":2.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147633541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Validation of Synthesa AI, a Large Language Model-Based Screening Tool for Systematic Reviews: Results From 9 Pharmacologic Studies. 基于语言模型的系统评价筛选工具——人工智能合成的验证：来自9项药理学研究的结果

IF 2.5 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2026-06-01 DOI: 10.1097/FJC.0000000000001768

Lefteris Teperikidis, Christos Trampoukis, Kyiakos Polymenakos

{"title":"Validation of Synthesa AI, a Large Language Model-Based Screening Tool for Systematic Reviews: Results From 9 Pharmacologic Studies.","authors":"Lefteris Teperikidis, Christos Trampoukis, Kyiakos Polymenakos","doi":"10.1097/FJC.0000000000001768","DOIUrl":"10.1097/FJC.0000000000001768","url":null,"abstract":"Abstract: Systematic review screening underpins the evidence base for pharmacology and drug development but remains burdensome, error-prone, and resource-intensive. Synthesa AI, a large language model-based abstract screening tool, was developed to streamline this process by providing a transparent and prompt-driven framework for abstract screening. In this validation study, Synthesa AI was tested across 17 benchmark meta-analyses on 9 therapeutic domains relevant to pharmacology and clinical pharmacotherapy. The tool screened 270,626 abstracts retrieved from PubMed and Scopus. Synthesa AI successfully identified all 163 benchmark-included studies, achieving a sensitivity of 100% (95% confidence interval: 97.7%-100.0%) and a specificity of 99.4% (95% confidence interval: 99.37%-99.42%). Importantly, it reduced reviewer workload by 91.7%, with only 1797 abstracts requiring manual review. Beyond replication, the tool identified 32 additional relevant studies that had been missed in the original reviews, representing a 19.6% increase in evidence yield. These findings highlight the potential of Synthesa AI to enhance pharmacological evidence synthesis by improving the reproducibility and comprehensiveness of systematic reviews used to evaluate drug efficacy, safety, and therapeutic positioning. Synthesa AI represents a transformative solution for living systematic reviews and large-scale evidence integration, offering a rigorous and efficient alternative to traditional human-led screening in pharmacology research.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"387-393"},"PeriodicalIF":2.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148199058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

When Three Is a Crowd: The Inflammatory Escalade of Triple ICI-Induced Myocarditis. 当三人为一群：三重ci诱导的心肌炎的炎症升级。

IF 2.5 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2026-06-01 DOI: 10.1097/FJC.0000000000001816

Nigeste Carter, Adolfo G Mauro

引用次数: 0

Ivabradine as a Treatment for Postural Orthostatic Tachycardia Syndrome: A Systematic Review. 伊伐布雷定治疗体位性心动过速综合征：系统综述。

IF 2.5 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2026-06-01 DOI: 10.1097/FJC.0000000000001784

Chun Shing Kwok, David Gillespie, Naeem Ur Rehman Qazi, Babak Nazari, Mark Hall, Gregory Y H Lip, Yoon K Loke, Adnan I Qureshi, Eric Holroyd, Satish R Raj

{"title":"Ivabradine as a Treatment for Postural Orthostatic Tachycardia Syndrome: A Systematic Review.","authors":"Chun Shing Kwok, David Gillespie, Naeem Ur Rehman Qazi, Babak Nazari, Mark Hall, Gregory Y H Lip, Yoon K Loke, Adnan I Qureshi, Eric Holroyd, Satish R Raj","doi":"10.1097/FJC.0000000000001784","DOIUrl":"10.1097/FJC.0000000000001784","url":null,"abstract":"Abstract: Ivabradine is one of several off-label treatments for patients with postural orthostatic tachycardia syndrome (POTS). We conducted a systematic review of the literature to identify studies that evaluate ivabradine treatment in patients with POTS. The results were narratively synthesized given methodological heterogeneity among the identified studies. There were 11 studies included in the analysis with 305 participants between 2008 and 2020. The only randomized trial of 22 patients showed that ivabradine improved heart rate compared with placebo, and there were symptomatic benefits in terms of physical functioning and social functioning. All studies suggested a reduction in heart rate with ivabradine treatment; the proportion of patients with symptomatic benefit ranged from 67% to 100%. One study using the Malmo POTS score found that ivabradine improved the total score, including key components such as light-headedness with standing, feeling faint, feeling rapid heart rate, and chest pain. Although 2 studies did not report side effects and 2 studies described no side effects, others reported adverse effects including bradycardia, nausea, worsening syncope, palpitations, flushing, light sensitivity, headache, light-headedness, fatigue, scalded tongue, itching and burning, and visual disturbance. In conclusion, there is low-quality evidence derived from small observational studies and 1 small randomized trial that ivabradine is effective in reducing heart rate and improving symptoms in patients with POTS. The exact role of ivabradine in treatment of POTS needs to be clarified in further randomized trials and more robust evidence.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"438-445"},"PeriodicalIF":2.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145714477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ling-Gui-Zhu-Gan Decoction Decreases Doxorubicin-Induced Cardiotoxicity by Regulating Inflammation Through the cGAS-STING Pathway. 灵桂竹肝汤通过cGAS-STING通路调节炎症，降低阿霉素诱导的心脏毒性。

IF 2.5 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2026-06-01 DOI: 10.1097/FJC.0000000000001826

Shu-Shu Wang, Ya-Li Yang, Hui-Min Ding, Min Ye, Jin-Ling Huang, Peng Zhou, Liang Wang

{"title":"Ling-Gui-Zhu-Gan Decoction Decreases Doxorubicin-Induced Cardiotoxicity by Regulating Inflammation Through the cGAS-STING Pathway.","authors":"Shu-Shu Wang, Ya-Li Yang, Hui-Min Ding, Min Ye, Jin-Ling Huang, Peng Zhou, Liang Wang","doi":"10.1097/FJC.0000000000001826","DOIUrl":"10.1097/FJC.0000000000001826","url":null,"abstract":"Abstract: Recent evidence has shown that the cyclic GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) signaling pathway mediated by nuclear factor E2-related factor 2 (Nrf2) contributes to the pathogenesis of doxorubicin (DOX)-induced cardiotoxicity. Ling-Gui-Zhu-Gan decoction (LGZGD) ameliorated DOX-cardiotoxicity in cardiomyocytes in our previous studies. In this study, the therapeutic effects of LGZGD that protect against DOX-induced cardiotoxicity in C57 male mice and HL-1 cells, and the underlying mechanisms were investigated. LGZGD-L (2.15 g/kg), LGZGD-M (4.29 g/kg), and LGZGD-H (8.58 g/kg) were administered daily in C57 male mice by gavage starting with the first intraperitoneal injection of DOX modeling for 4 weeks. LGZGD reduced the inflammatory cell infiltration, collagen of myocardial tissue, and collagen fiber deposition, increased ejection fraction and fractional shortening, decreased left ventricular internal dimension in end-systole and left ventricular internal dimension in end-diastole, and reduced mitochondrial damage. LGZGD also decreased creatine kinase and malondialdehyde activities, and increased the content of superoxide dismutase, increased the Nrf2 expressions, and reduce expressions of cGAS, STING, nucleotide-binding oligomerization domain-, leucine-rich repeat-, and pyrin domain-containing receptor 3 (NLRP3), cysteine aspartate protease-1 (Caspase-1), gasdermin D (GSDMD), and GSDMD-N-terminal domain (GSDMD-N). In HL-1 cells, LGZGD suppressed DOX-induced oxidative stress injury and the mitochondrial membrane potential. LGZGD inhibited dynamin-related protein 1, an increased optic atrophy 1, and Nrf2 expressions, as evidenced by decreased NLRP3, Caspase1, and GSDMD gene and protein expressions. In summary, we reveal a novel aspect of the cardiovascular protective effect of LGZGD, regulating the cGAS-STING pathway.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"456-470"},"PeriodicalIF":2.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147632786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rivaroxaban Safety and Persistence in Patients With Nonvalvular Atrial Fibrillation: Prospective, Observational, Cohort, Postmarketing Study. 利伐沙班在非瓣膜性房颤患者中的安全性和依从性：前瞻性、观察性、队列、上市后研究

IF 2.5 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2026-06-01 DOI: 10.1097/FJC.0000000000001829

Elnur Smajić, Elmir Jahić, Denis Mršić, Behija Berberović-Hukeljić, Almin Handanagić, Džan Ahmed Jesenković, Meliha Mehić, Amna Tanović Avdić, Aziz Šukalo, Una Glamočlija

{"title":"Rivaroxaban Safety and Persistence in Patients With Nonvalvular Atrial Fibrillation: Prospective, Observational, Cohort, Postmarketing Study.","authors":"Elnur Smajić, Elmir Jahić, Denis Mršić, Behija Berberović-Hukeljić, Almin Handanagić, Džan Ahmed Jesenković, Meliha Mehić, Amna Tanović Avdić, Aziz Šukalo, Una Glamočlija","doi":"10.1097/FJC.0000000000001829","DOIUrl":"10.1097/FJC.0000000000001829","url":null,"abstract":"Abstract: The aim of this study was to evaluate real-world rivaroxaban safety and persistence in patients with nonvalvular atrial fibrillation (NVAF). A prospective, observational, cohort, postmarketing study was conducted during a 6-month period. The primary outcome was bleeding, including major bleeding, nonmajor bleeding, and fecal occult blood test positivity. Secondary outcomes included nonbleeding adverse reactions, changes in laboratory parameters, and therapy persistence presented by discontinuation rate. We included 1184 patients evaluated at baseline and at 1, 3, and 6 months. During follow-up, cumulative incidences (95% confidence interval) were 0.9% (0.5%-1.7%) for major bleeding, 13.3% (11.4%-15.3%) for nonmajor bleeding, and 3.4% (2.4%-4.6%) for fecal occult blood positivity. Other adverse drug reactions were infrequent and mild, most commonly headache and fatigue, and no clinically relevant deterioration of laboratory parameters was observed. Persistence was high, with 19 (1.6%) patients excluded during the six-month follow-up. This real-world study supports the favorable safety profile and high patient persistence to rivaroxaban in NVAF. Continued monitoring of bleeding risk and enhanced patient education on persistence remain crucial for optimal outcomes.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"446-455"},"PeriodicalIF":2.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147772693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Emerging Role of Artificial Intelligence in Drug Discovery and Development: Implications for Cardiovascular Pharmacology. 人工智能在药物发现和开发中的新兴作用：对心血管药理学的影响。

IF 2.5 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2026-06-01 DOI: 10.1097/FJC.0000000000001803

Alaa Abdelhamid, Dima Nasrallah, Yaman Al-Haneedi, Esraa Ahmed, Ali H Eid

{"title":"The Emerging Role of Artificial Intelligence in Drug Discovery and Development: Implications for Cardiovascular Pharmacology.","authors":"Alaa Abdelhamid, Dima Nasrallah, Yaman Al-Haneedi, Esraa Ahmed, Ali H Eid","doi":"10.1097/FJC.0000000000001803","DOIUrl":"10.1097/FJC.0000000000001803","url":null,"abstract":"Abstract: Cardiovascular diseases remain the leading cause of global morbidity and mortality, highlighting the urgent need for more efficient, precise, and cost-effective drug development strategies. Traditional drug discovery pipelines face persistent challenges, including elevated expenses, prolonged timelines, and high attrition rates, particularly with the complex pathophysiology of cardiovascular conditions. Artificial intelligence (AI) has emerged as a transformative force capable of addressing these barriers across all stages of cardiovascular drug development. This review explores the integration of AI in target identification, compound screening, drug design, pharmacokinetic and toxicity prediction, and clinical trial optimization. We highlight state-of-the-art AI tools such as large language models (eg, BioGPT, Geneformer), generative frameworks (eg, Generative Tensorial Reinforcement Learning, Variational Autoencoders, Generative Adversarial Networks), and neural ordinary differential equations, illustrating their ability to accelerate drug discovery, personalize therapy, and improve clinical success rates. In the context of clinical trials, platforms such as Trial Pathfinder have been used to optimize patient recruitment and improve generalizability. Despite these advancements, several challenges persist, particularly those related to data quality, population representativeness, interpretability, and regulatory oversight. Future directions involving the integration of AI with quantum computing, blockchain technology, and precision medicine offer additional opportunities to advance the field. Collectively, these innovations mark a paradigm shift toward faster, safer, and more personalized cardiovascular drug development.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"368-386"},"PeriodicalIF":2.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146112949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sonodynamic Therapy Attenuates TLR4/NF-κB Signaling in Epicardial Adipose Tissue of Atrial Fibrillation: Insights From Animal Models, scRNA-seq, and Mendelian Randomization. 声动力治疗减弱心房颤动心外膜脂肪组织中的TLR4/NF-κB信号：来自动物模型、scrna序列和孟德尔随机化的见解

IF 2.5 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2026-06-01 DOI: 10.1097/FJC.0000000000001825

Penghao Gao, Wei Wang, Weifa Wang, Mengyang Liu, Guodong Wu, Yanfeng Tian, Dechun Yin, Ye Tian

{"title":"Sonodynamic Therapy Attenuates TLR4/NF-κB Signaling in Epicardial Adipose Tissue of Atrial Fibrillation: Insights From Animal Models, scRNA-seq, and Mendelian Randomization.","authors":"Penghao Gao, Wei Wang, Weifa Wang, Mengyang Liu, Guodong Wu, Yanfeng Tian, Dechun Yin, Ye Tian","doi":"10.1097/FJC.0000000000001825","DOIUrl":"10.1097/FJC.0000000000001825","url":null,"abstract":"Abstract: Atrial fibrillation (AF) is the most common arrhythmia leading to cardioembolic stroke, with inflammation of epicardial adipose tissue (EAT) contributing to its pathogenesis. However, current therapies cannot specifically target EAT inflammation to alleviate AF. This study investigated the effects of sonodynamic therapy (SDT) on reducing macrophage-mediated inflammation in the EAT of rabbit AF models and explored its potential clinical application in AF patients. Rabbits were assigned to sham, paced (600 beats per minute for 4 weeks), and SDT groups. Macrophage infiltration and collagen deposition were evaluated using rat anti-rabbit macrophage antibody 11 immunohistochemistry and Masson staining, respectively. Transcriptomic analysis and network pharmacology identified toll-like receptor 4/nuclear factor-κB pathway genes (including CXCL8 and CCL2 ) as SDT targets for AF treatment, which were validated by Western blot and quantitative real-time polymerase chain reaction. Single-cell sequencing of human EAT and right atrial appendage confirmed the expression of these SDT-targeted genes in macrophages from patients with AF. Mendelian randomization demonstrated that elevated plasma CXCL8, but not CCL2, was associated with an increased risk of AF. SDT reduced macrophage infiltration, fibrosis, and toll-like receptor 4/nuclear factor-κB-mediated inflammation, supporting its therapeutic potential in AF by modulation of EAT inflammation.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"501-513"},"PeriodicalIF":2.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147645567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

When Phenotyping Is the Intervention: Personalized Treatment of Diffuse Coronary Artery Disease. 当表型是干预：弥漫性冠状动脉疾病的个体化治疗。

IF 2.2 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2026-06-01 DOI: 10.1097/FJC.0000000000001809

Salvatore Giordano, Alberto Morello, Giuseppe Biondi-Zoccai, Nicola Corcione

引用次数: 0